Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy

Successfully combating the COVID-19 pandemic depends on mass vaccination with suitable vaccines to achieve herd immunity. Here, we describe COVI-VAC, the only live attenuated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine currently in clinical development. COVI-VAC was develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying, Yang, Chen, Song, Yutong, Coleman, J. Robert, Stawowczyk, Marcin, Tafrova, Juliana, Tasker, Sybil, Boltz, David, Baker, Robert, Garcia, Liliana, Seale, Olivia, Kushnir, Anna, Wimmer, Eckard, Mueller, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307828/
https://www.ncbi.nlm.nih.gov/pubmed/34193524
http://dx.doi.org/10.1073/pnas.2102775118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307828/
https://www.ncbi.nlm.nih.gov/pubmed/34193524
http://dx.doi.org/10.1073/pnas.2102775118

Ejemplares similares